Eli Lilly’s head of diabetes and obesity unit to retire

This post was originally published on this site

Mason oversaw the late-stage development of tirzepatide, Lilly’s potential blockbuster that is sold under the brand name Mounjaro for diabetes and is under U.S. regulatory review for obesity.

Lilly said Patrik Jonsson, president of Lilly USA, will take over Mason’s role.

The company’s shares were down 1% in premarket trading.